Summary Most antibodies isolated from individuals with coronavirus disease 2019 (COVID-19) are specific to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, COVA1-16 is a relatively rare antibody that also cross-neutralizes SARS-CoV. Here, we determined a crystal structure of the COVA1-16 antibody fragment (Fab) with the SARS-CoV-2 receptor-binding domain (RBD) and negative-stain electron microscopy reconstructions with the spike glycoprotein trimer to elucidate the structural basis of its cross-reactivity. COVA1-16 binds a highly conserved epitope on the SARS-CoV-2 RBD, mainly through a long complementarity-determining region (CDR) H3, and competes with the angiotensin-converting enzyme 2 (ACE2) receptor because of steric hindrance rather than epitope overlap. COVA1-16 binds to a flexible up conformation of the RBD on the spike and relies on antibody avidity for neutralization. These findings, along with the structural and functional rationale for epitope conservation, provide insights for development of more universal SARS-like coronavirus vaccines and therapies. Graphical Abstract Highlights • X-ray and EM structures of cross-neutralizing antibody COVA1-16 with SARS-CoV-2 RBD • COVA1-16 binding to SARS-CoV-2 RBD is dominated by CDR H3 • COVA1-16 binds to a highly conserved non-RBS epitope but still competes with ACE2 • IgG avidity is the key for the cross-neutralization activity of COVA1-16 COVA1-16 is a SARS-CoV-2 antibody from an individual with COVID-19 that cross-neutralizes SARS-CoV. Liu et al. reveal that COVA1-16 binds to a highly conserved epitope using a long CDR H3, where its approach angle sterically blocks ACE2 from engaging the RBS. Virus neutralization by COVA1-16 is driven by IgG avidity.
【초록키워드】 COVID-19, coronavirus disease, Structure, SARS-CoV-2, IgG, Coronavirus disease 2019, ACE2, coronavirus, antibody, SARS-CoV, neutralization, spike glycoprotein, severe acute respiratory syndrome Coronavirus, angiotensin-converting enzyme 2, cross-reactivity, X-ray, SARS-CoV-2 antibody, RBD, Virus neutralization, receptor, respiratory, crystal structure, epitope, CDR, Therapies, Antibody avidity, binding, Fab, cross-neutralize, Angiotensin-converting enzyme, angiotensin, SARS-CoV-2 RBD, Coronavirus vaccines, acute respiratory syndrome, overlap, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, individual, domain, trimer, MOST, epitope conservation, cross-neutralization activity, block, COVA1-16, approach, steric hindrance, CDR H3, negative-stain electron microscopy, complementarity-determining region, bind, flexible, conserved, functional, the RBD, driven by, antibody COVA1-16, cross-neutralizing, individual with COVID-19, RBS, SARS-like coronavirus vaccine, the SARS-CoV-2, 【제목키워드】 SARS-CoV-2, avidity, Mediated, Site,